Treatment Macular Degeneration - Yahoo Search Results

- Gene therapy for macular degeneration: Uses and more
  Medical News Today· 3 days ago
  Several gene therapies are undergoing clinical trials. In this article, learn more about gene therapy and its potential role in treating macular ...
- Measuring levels of proteins in eye fluid may accurately predict need for lifelong macular ...
  Medical Xpress· 3 days ago
  In a study of eye fluid from 38 patients, Johns Hopkins Medicine researchers say they have found...
- Macular degeneration and diabetes: Links and more
  Medical News Today· 3 days ago
  Macular degeneration describes a loss of central vision due to damage to part of the retina. People with diabetes might have an increased risk of...
- OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of...
  Morningstar· 2 days ago
  The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
- NHS delays: Avoidable blindness fears over eye care waits
  BBC News· 4 days ago
  A "tide of avoidable blindness" could sweep Wales if eye care services are not reformed, a...
- 2-Year Faricimab Results: 'Visual Gains With Fewer Injections'
  Medscape· 6 days ago
  The trials compared two dosing regimens of faricimab — including a personalized treatment interval...
- Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted
  Zacks via Yahoo Finance· 2 days ago
  A potential approval for the 16-week dosing regimen would provide a longer treatment interval and...
- NVISION® Eye Centers Continues National Expansion
  WCMH Columbus· 2 days ago
  ALISO VIEJO, Calif. , June 30, 2022 /PRNewswire/ -- NVISION® Eye Centers is pleased to announce the addition of two retina practices to the NVISION family – Salt Lake Retina in Salt Lake City ...
- EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic...
  WFMZ Eastern Pennsylvania and Western New Jersey· 4 days ago
  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration...
- Graybug (GRAY) to Review Strategic Alternatives, Stock Up
  Zacks· 4 days ago
  Free Report) announced that its board of directors is willing to conduct a comprehensive review of strategic options and alternatives focused on maximizing shareholders’ value of the company ...